
|Videos|June 23, 2017
Dr. Grignani on the Patient Population of Trabectedin for Sarcoma
Author(s)Giovanni Grignani, MD
Giovanni Grignani, MD, medical oncologist, Candiolo Cancer Institute IRCCS, discusses the intended patient population for trabectedin (Yondelis) in the treatment of sarcoma.
Advertisement
Giovanni Grignani, MD, medical oncologist, Candiolo Cancer Institute IRCCS, discusses the intended patient population for trabectedin (Yondelis) in the treatment of sarcoma.
This is a new option that oncologists should consider for frail patients who have soft tissue sarcoma.
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
The OncFive: Top Oncology Articles for the Week of 5/31
3
CELMoDs and Bispecifics Break Through Across Lymphomas and Leukemias at EHA 2026
4
From Toilet Cleaner to Thoracic Oncologist and Patient: How Ross Camidge Built a Life Worth Loving
5




































































